Page 2 - Afmd News Today

Affimed (NASDAQ:AFMD – Get Free Report) has been given an average rating of “Moderate Buy” by the eight brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price among analysts that have […]

StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a research report report published on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock. Several other research firms have also commented on AFMD. HC Wainwright reiterated a buy rating and issued a $5.00 target price on shares of Affimed […]

StockNews.com assumed coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a report released on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on AFMD. Berenberg Bank restated a buy rating and set a $6.00 price objective on shares […]

Shares of Affimed (NASDAQ:AFMD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among […]

Affimed (NASDAQ:AFMD – Get Free Report) was the recipient of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 2,160,000 shares, a decrease of 8.9% from the September 15th total of 2,370,000 shares. Based on an average daily volume of 485,400 shares, the days-to-cover […]

StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a research note released on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. AFMD has been the subject of several other reports. Truist Financial reduced their target price on Affimed from $8.00 to $6.00 and set a buy […]

StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD – Free Report) in a report released on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Several other equities research analysts have also recently commented on AFMD. Truist Financial lowered their price target on Affimed from $8.00 to $6.00 and set a […]

Affimed (NASDAQ:AFMD – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among […]

Shares of Affimed (NASDAQ:AFMD – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price objective […]

Cantor Fitzgerald reaffirmed their overweight rating on shares of Affimed (NASDAQ:AFMD – Free Report) in a report published on Monday morning, Benzinga reports. The brokerage currently has a $7.00 price objective on the biopharmaceutical company’s stock. A number of other equities analysts also recently commented on the company. Berenberg Bank reissued a buy rating and […]